Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 166 entries
Sorted by: Best Match Show Resources per page
Unlike in clear cell renal cell carcinoma, KRAS is not mutated in multilocular cystic clear cell renal cell neoplasm of low potential.

Virchows Archiv : an international journal of pathology

Raspollini MR, Castiglione F, Martignoni G, Cheng L, Montironi R, Lopez-Beltran A.
PMID: 26438300
Virchows Arch. 2015 Dec;467(6):687-693. doi: 10.1007/s00428-015-1859-8. Epub 2015 Oct 05.

The recent International Society Urological Pathology (ISUP) Vancouver classification of renal neoplasia distinguishes between clear cell renal cell carcinoma (CCRCC) and multilocular cystic clear cell renal cell neoplasm of low malignant potential (mcCCRCNLMP). Current data supports the latter being...

Cite
Raspollini MR, Castiglione F, Martignoni G, et al. Unlike in clear cell renal cell carcinoma, KRAS is not mutated in multilocular cystic clear cell renal cell neoplasm of low potential. Virchows Arch. 2015;467(6):687-693doi: 10.1007/s00428-015-1859-8.
Raspollini, M. R., Castiglione, F., Martignoni, G., Cheng, L., Montironi, R., & Lopez-Beltran, A. (2015). Unlike in clear cell renal cell carcinoma, KRAS is not mutated in multilocular cystic clear cell renal cell neoplasm of low potential. Virchows Archiv : an international journal of pathology, 467(6), 687-693. https://doi.org/10.1007/s00428-015-1859-8
Raspollini, Maria Rosaria, et al. "Unlike in clear cell renal cell carcinoma, KRAS is not mutated in multilocular cystic clear cell renal cell neoplasm of low potential." Virchows Archiv : an international journal of pathology vol. 467,6 (2015): 687-693. doi: https://doi.org/10.1007/s00428-015-1859-8
Raspollini MR, Castiglione F, Martignoni G, Cheng L, Montironi R, Lopez-Beltran A. Unlike in clear cell renal cell carcinoma, KRAS is not mutated in multilocular cystic clear cell renal cell neoplasm of low potential. Virchows Arch. 2015 Dec;467(6):687-693. doi: 10.1007/s00428-015-1859-8. Epub 2015 Oct 05. PMID: 26438300.
Copy Download .nbib Format: NLM
Prostatic intraepithelial neoplasia and prostate cancer: analytical evaluation.

Advances in clinical pathology : the official journal of Adriatic Society of Pathology

Colanzi P, Santinelli A, Mazzucchelli R, Pomante R, Montironi R.
PMID: 10358369
Adv Clin Path. 1998 Oct;2(4):271-284.

For urologists and pathologists one of the two main issues in prostate pathology is the identification of those prognostic factors that could predict the exact outcome of individual patients with prostate cancer (PC). Therefore, the goal is to tailor...

Cite
Colanzi P, Santinelli A, Mazzucchelli R, et al. Prostatic intraepithelial neoplasia and prostate cancer: analytical evaluation. Adv Clin Path. 1998;2(4):271-284
Colanzi, P., Santinelli, A., Mazzucchelli, R., Pomante, R., & Montironi, R. (1998). Prostatic intraepithelial neoplasia and prostate cancer: analytical evaluation. Advances in clinical pathology : the official journal of Adriatic Society of Pathology, 2(4), 271-284.
Colanzi, et al. "Prostatic intraepithelial neoplasia and prostate cancer: analytical evaluation." Advances in clinical pathology : the official journal of Adriatic Society of Pathology vol. 2,4 (1998): 271-284.
Colanzi P, Santinelli A, Mazzucchelli R, Pomante R, Montironi R. Prostatic intraepithelial neoplasia and prostate cancer: analytical evaluation. Adv Clin Path. 1998 Oct;2(4):271-284. PMID: 10358369.
Copy Download .nbib Format: NLM
Biochemical and computational approaches to improve the clinical treatment of dopa decarboxylase-related diseases: an overview.

The open biochemistry journal

Cellini B, Montioli R, Oppici E, Voltattorni CB.
PMID: 23264832
Open Biochem J. 2012;6:131-8. doi: 10.2174/1874091X01206010131. Epub 2012 Dec 11.

Dopa decarboxylase (DDC) is a pyridoxal 5'-phosphate (PLP)-dependent enzyme that by catalyzing the decarboxylation of L-Dopa and L-5-hydroxytryptophan produces the neurotransmitters dopamine and serotonin. The functional properties of pig kidney and human DDC enzymes have been extensively characterized, and...

Cite
Cellini B, Montioli R, Oppici E, et al. Biochemical and computational approaches to improve the clinical treatment of dopa decarboxylase-related diseases: an overview. Open Biochem J. 2012;6:131-8doi: 10.2174/1874091X01206010131.
Cellini, B., Montioli, R., Oppici, E., & Voltattorni, C. B. (2012). Biochemical and computational approaches to improve the clinical treatment of dopa decarboxylase-related diseases: an overview. The open biochemistry journal, 6131-8. https://doi.org/10.2174/1874091X01206010131
Cellini, Barbara, et al. "Biochemical and computational approaches to improve the clinical treatment of dopa decarboxylase-related diseases: an overview." The open biochemistry journal vol. 6 (2012): 131-8. doi: https://doi.org/10.2174/1874091X01206010131
Cellini B, Montioli R, Oppici E, Voltattorni CB. Biochemical and computational approaches to improve the clinical treatment of dopa decarboxylase-related diseases: an overview. Open Biochem J. 2012;6:131-8. doi: 10.2174/1874091X01206010131. Epub 2012 Dec 11. PMID: 23264832; PMCID: PMC3528064.
Copy Download .nbib Format: NLM
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia.

The American journal of surgical pathology

Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK, Zhou M, Argani P.
PMID: 24025519
Am J Surg Pathol. 2013 Oct;37(10):1469-89. doi: 10.1097/PAS.0b013e318299f2d1.

The classification working group of the International Society of Urological Pathology consensus conference on renal neoplasia was in charge of making recommendations regarding additions and changes to the current World Health Organization Classification of Renal Tumors (2004). Members of...

Cite
Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol. 2013;37(10):1469-89doi: 10.1097/PAS.0b013e318299f2d1.
Srigley, J. R., Delahunt, B., Eble, J. N., Egevad, L., Epstein, J. I., Grignon, D., Hes, O., Moch, H., Montironi, R., Tickoo, S. K., Zhou, M., Argani, P. (2013). The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. The American journal of surgical pathology, 37(10), 1469-89. https://doi.org/10.1097/PAS.0b013e318299f2d1
Srigley, John R, et al. "The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia." The American journal of surgical pathology vol. 37,10 (2013): 1469-89. doi: https://doi.org/10.1097/PAS.0b013e318299f2d1
Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK, Zhou M, Argani P. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol. 2013 Oct;37(10):1469-89. doi: 10.1097/PAS.0b013e318299f2d1. PMID: 24025519.
Copy Download .nbib Format: NLM
Words of wisdom. Re: "No pay, no play": the end of professional ethics in pathology?.

European urology

Montironi R, Lopez-Beltran A, Cheng L, Scarpelli M.
PMID: 22186346
Eur Urol. 2012 Feb;61(2):424-5. doi: 10.1016/j.eururo.2011.11.023.

No abstract available.

Cite
Montironi R, Lopez-Beltran A, Cheng L, et al. Words of wisdom. Re: "No pay, no play": the end of professional ethics in pathology?. Eur Urol. 2012;61(2):424-5doi: 10.1016/j.eururo.2011.11.023.
Montironi, R., Lopez-Beltran, A., Cheng, L., & Scarpelli, M. (2012). Words of wisdom. Re: "No pay, no play": the end of professional ethics in pathology?. European urology, 61(2), 424-5. https://doi.org/10.1016/j.eururo.2011.11.023
Montironi, Rodolfo, et al. "Words of wisdom. Re: "No pay, no play": the end of professional ethics in pathology?." European urology vol. 61,2 (2012): 424-5. doi: https://doi.org/10.1016/j.eururo.2011.11.023
Montironi R, Lopez-Beltran A, Cheng L, Scarpelli M. Words of wisdom. Re: "No pay, no play": the end of professional ethics in pathology?. Eur Urol. 2012 Feb;61(2):424-5. doi: 10.1016/j.eururo.2011.11.023. PMID: 22186346.
Copy Download .nbib Format: NLM
Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer.

Frontiers in oncology

Di Nunno V, Gatto L, Santoni M, Cimadamore A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R, Massari F.
PMID: 30319966
Front Oncol. 2018 Sep 24;8:397. doi: 10.3389/fonc.2018.00397. eCollection 2018.

Management of localized and advanced prostate cancer benefits from several therapeutic options with a surprising improvement in terms of clinical outcome. The selection of patients more likely to benefit from a specific approach still remains a key issue as...

Cite
Di Nunno V, Gatto L, Santoni M, et al. Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. Front Oncol. 2018;8:397doi: 10.3389/fonc.2018.00397.
Di Nunno, V., Gatto, L., Santoni, M., Cimadamore, A., Lopez-Beltran, A., Cheng, L., Scarpelli, M., Montironi, R., & Massari, F. (2018). Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. Frontiers in oncology, 8397. https://doi.org/10.3389/fonc.2018.00397
Di Nunno, Vincenzo, et al. "Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer." Frontiers in oncology vol. 8 (2018): 397. doi: https://doi.org/10.3389/fonc.2018.00397
Di Nunno V, Gatto L, Santoni M, Cimadamore A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R, Massari F. Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. Front Oncol. 2018 Sep 24;8:397. doi: 10.3389/fonc.2018.00397. eCollection 2018. PMID: 30319966; PMCID: PMC6165898.
Copy Download .nbib Format: NLM
Attitudes of Surgeons toward Elderly Cancer Patients: A Survey from the SIOG Surgical Task Force.

Visceral medicine

Saur NM, Montroni I, Ghignone F, Ugolini G, Audisio RA.
PMID: 29034254
Visc Med. 2017 Aug;33(4):262-266. doi: 10.1159/000477641. Epub 2017 Aug 07.

Cancer care in elderly patients is complex. A recent survey showed that among mostly academic surgeons, practice patterns varied in the care of elderly patients. The authors suggested three areas of intervention in improving care of this population: frailty...

Cite
Saur NM, Montroni I, Ghignone F, et al. Attitudes of Surgeons toward Elderly Cancer Patients: A Survey from the SIOG Surgical Task Force. Visc Med. 2017;33(4):262-266doi: 10.1159/000477641.
Saur, N. M., Montroni, I., Ghignone, F., Ugolini, G., & Audisio, R. A. (2017). Attitudes of Surgeons toward Elderly Cancer Patients: A Survey from the SIOG Surgical Task Force. Visceral medicine, 33(4), 262-266. https://doi.org/10.1159/000477641
Saur, Nicole M, et al. "Attitudes of Surgeons toward Elderly Cancer Patients: A Survey from the SIOG Surgical Task Force." Visceral medicine vol. 33,4 (2017): 262-266. doi: https://doi.org/10.1159/000477641
Saur NM, Montroni I, Ghignone F, Ugolini G, Audisio RA. Attitudes of Surgeons toward Elderly Cancer Patients: A Survey from the SIOG Surgical Task Force. Visc Med. 2017 Aug;33(4):262-266. doi: 10.1159/000477641. Epub 2017 Aug 07. PMID: 29034254; PMCID: PMC5624262.
Copy Download .nbib Format: NLM
Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians.

Asian journal of andrology

Gasparrini S, Cimadamore A, Scarpelli M, Massari F, Doria A, Mazzucchelli R, Cheng L, Lopez-Beltran A, Montironi R.
PMID: 28782737
Asian J Androl. 2017 Aug 04; doi: 10.4103/aja.aja_24_17. Epub 2017 Aug 04.

The Gleason grading system for prostate cancer (PCa) was developed in the 1960s by DF Gleason. Due to changes in PCa detection and treatment, the application of the Gleason grading system has changed considerably in pathology routine practice. Two...

Cite
Gasparrini S, Cimadamore A, Scarpelli M, et al. Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians. Asian J Androl. 2017;doi: 10.4103/aja.aja_24_17.
Gasparrini, S., Cimadamore, A., Scarpelli, M., Massari, F., Doria, A., Mazzucchelli, R., Cheng, L., Lopez-Beltran, A., & Montironi, R. (2017). Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians. Asian journal of andrology, . https://doi.org/10.4103/aja.aja_24_17
Gasparrini, Silvia, et al. "Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians." Asian journal of andrology vol. (2017). doi: https://doi.org/10.4103/aja.aja_24_17
Gasparrini S, Cimadamore A, Scarpelli M, Massari F, Doria A, Mazzucchelli R, Cheng L, Lopez-Beltran A, Montironi R. Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians. Asian J Androl. 2017 Aug 04; doi: 10.4103/aja.aja_24_17. Epub 2017 Aug 04. PMID: 28782737; PMCID: PMC6337944.
Copy Download .nbib Format: NLM
Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus.

Future oncology (London, England)

Fisher KW, Lopez-Beltran A, Montironi R, Cheng L.
PMID: 26338658
Future Oncol. 2015 Oct;11(19):2711-2719. doi: 10.2217/fon.15.219. Epub 2015 Sep 04.

Colorectal cancer is the third most lethal cancer in men and women in the USA. Although surgical resection is the mainstay of treatment, many patients develop local and widely metastatic disease and become resistant to conventional chemotherapeutics. Recent comprehensive...

Cite
Fisher KW, Lopez-Beltran A, Montironi R, et al. Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus. Future Oncol. 2015;11(19):2711-2719doi: 10.2217/fon.15.219.
Fisher, K. W., Lopez-Beltran, A., Montironi, R., & Cheng, L. (2015). Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus. Future oncology (London, England), 11(19), 2711-2719. https://doi.org/10.2217/fon.15.219
Fisher, Kurt W, et al. "Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus." Future oncology (London, England) vol. 11,19 (2015): 2711-2719. doi: https://doi.org/10.2217/fon.15.219
Fisher KW, Lopez-Beltran A, Montironi R, Cheng L. Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus. Future Oncol. 2015 Oct;11(19):2711-2719. doi: 10.2217/fon.15.219. Epub 2015 Sep 04. PMID: 26338658.
Copy Download .nbib Format: NLM
Corrigendum to "The Importance of Interaction Between Urologists and Pathologists in Incidental Prostate Cancer Management" [Eur Eurol 2011;60;75-7].

European urology

Capitanio U, Cheng L, Lopez-Beltran A, Scarpelli M, Freschi M, Montorsi F, Montironi R.
PMID: 27989299
Eur Urol. 2012 Aug;62(2):e47. doi: 10.1016/j.eururo.2012.05.001. Epub 2012 May 08.

No abstract available.

Cite
Capitanio U, Cheng L, Lopez-Beltran A, et al. Corrigendum to "The Importance of Interaction Between Urologists and Pathologists in Incidental Prostate Cancer Management" [Eur Eurol 2011;60;75-7]. Eur Urol. 2012;62(2):e47doi: 10.1016/j.eururo.2012.05.001.
Capitanio, U., Cheng, L., Lopez-Beltran, A., Scarpelli, M., Freschi, M., Montorsi, F., & Montironi, R. (2012). Corrigendum to "The Importance of Interaction Between Urologists and Pathologists in Incidental Prostate Cancer Management" [Eur Eurol 2011;60;75-7]. European urology, 62(2), e47. https://doi.org/10.1016/j.eururo.2012.05.001
Capitanio, Umberto, et al. "Corrigendum to "The Importance of Interaction Between Urologists and Pathologists in Incidental Prostate Cancer Management" [Eur Eurol 2011;60;75-7]." European urology vol. 62,2 (2012): e47. doi: https://doi.org/10.1016/j.eururo.2012.05.001
Capitanio U, Cheng L, Lopez-Beltran A, Scarpelli M, Freschi M, Montorsi F, Montironi R. Corrigendum to "The Importance of Interaction Between Urologists and Pathologists in Incidental Prostate Cancer Management" [Eur Eurol 2011;60;75-7]. Eur Urol. 2012 Aug;62(2):e47. doi: 10.1016/j.eururo.2012.05.001. Epub 2012 May 08. PMID: 27989299.
Copy Download .nbib Format: NLM
The Identification of Immunological Biomarkers in Kidney Cancers.

Frontiers in oncology

Lopez-Beltran A, Henriques V, Cimadamore A, Santoni M, Cheng L, Gevaert T, Blanca A, Massari F, Scarpelli M, Montironi R.
PMID: 30450335
Front Oncol. 2018 Nov 02;8:456. doi: 10.3389/fonc.2018.00456. eCollection 2018.

The recent approval of several agents have revolutionized the scenario of therapeutic management of metastatic renal cell carcinoma (RCC) allowing us to reach important clinical end points with extended patients' survival. Actually, every new drug approved has represented an...

Cite
Lopez-Beltran A, Henriques V, Cimadamore A, et al. The Identification of Immunological Biomarkers in Kidney Cancers. Front Oncol. 2018;8:456doi: 10.3389/fonc.2018.00456.
Lopez-Beltran, A., Henriques, V., Cimadamore, A., Santoni, M., Cheng, L., Gevaert, T., Blanca, A., Massari, F., Scarpelli, M., & Montironi, R. (2018). The Identification of Immunological Biomarkers in Kidney Cancers. Frontiers in oncology, 8456. https://doi.org/10.3389/fonc.2018.00456
Lopez-Beltran, Antonio, et al. "The Identification of Immunological Biomarkers in Kidney Cancers." Frontiers in oncology vol. 8 (2018): 456. doi: https://doi.org/10.3389/fonc.2018.00456
Lopez-Beltran A, Henriques V, Cimadamore A, Santoni M, Cheng L, Gevaert T, Blanca A, Massari F, Scarpelli M, Montironi R. The Identification of Immunological Biomarkers in Kidney Cancers. Front Oncol. 2018 Nov 02;8:456. doi: 10.3389/fonc.2018.00456. eCollection 2018. PMID: 30450335; PMCID: PMC6225533.
Copy Download .nbib Format: NLM
PD-L1 assessment in urothelial carcinoma: a practical approach.

Annals of translational medicine

Eckstein M, Cimadamore A, Hartmann A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R, Gevaert T.
PMID: 31930091
Ann Transl Med. 2019 Nov;7(22):690. doi: 10.21037/atm.2019.10.24.

Five programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors are currently approved for treatment of locally advanced or metastatic urothelial carcinoma of the bladder and the upper urinary tract. Due to restrictions by the FDA and EMA first-line treatment with...

Cite
Eckstein M, Cimadamore A, Hartmann A, et al. PD-L1 assessment in urothelial carcinoma: a practical approach. Ann Transl Med. 2019;7(22):690doi: 10.21037/atm.2019.10.24.
Eckstein, M., Cimadamore, A., Hartmann, A., Lopez-Beltran, A., Cheng, L., Scarpelli, M., Montironi, R., & Gevaert, T. (2019). PD-L1 assessment in urothelial carcinoma: a practical approach. Annals of translational medicine, 7(22), 690. https://doi.org/10.21037/atm.2019.10.24
Eckstein, Markus, et al. "PD-L1 assessment in urothelial carcinoma: a practical approach." Annals of translational medicine vol. 7,22 (2019): 690. doi: https://doi.org/10.21037/atm.2019.10.24
Eckstein M, Cimadamore A, Hartmann A, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R, Gevaert T. PD-L1 assessment in urothelial carcinoma: a practical approach. Ann Transl Med. 2019 Nov;7(22):690. doi: 10.21037/atm.2019.10.24. PMID: 31930091; PMCID: PMC6944605.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 166 entries